LumiraDx Limited (LMDX)
Company Description
LumiraDx Limited operates as a point of care diagnostics company.
The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers.
It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care.
The company has approximately 30 tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions from the lab to point of need.
Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease.
The company was founded in 2014 and is headquartered in London, the United Kingdom.
| Country | GB |
| IPO Date | Mar 19, 2021 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 1,210 |
| CEO | Veronique Ameye EMBA, Esq., M.B.A. |
Contact Details
Address: 3 More London Riverside London, GB | |
| Website | https://www.lumiradx.com |
Stock Details
| Ticker Symbol | LMDX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001685428 |
| CUSIP Number | G5709L109 |
| ISIN Number | KYG5709L1095 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ron Zwanziger | Co-Founder, Chairman & Chief Executive Officer |
| Veronique Ameye EMBA, Esq., M.B.A. | Chief Executive Officer & General Counsel |
| Veronique Ameye Esq., M.B.A. | Deputy Chief Executive Officer & General Counsel |
| Veronique Ameye M.B.A. | Deputy Chief Executive Officer & Gen. Counsel |
| Dorian LeBlanc CPA | Chief Financial Officer & Vice President of Global Operations |
| Dr. David Scott Ph.D. | Co-Founder, Chief Technology Officer & Director |
| Andy Ward | National Sales Director - UK |
| Colleen McMillen | Vice President of Communications |
| David Walton DMS | Chief Commercial Officer |
| Dr. Jerome F. McAleer Ph.D. | Co-Founder, Chief Scientist & Director |
| Dr. Nigel Lindner | Chief Innovation Officer |
| Giffin Daughtridge | President of North America Commercial Operations & Global Molecular Solutions |
| Melissa Garcia | Vice President & Corporate Counsel |
| Peter Scheu | Pres of North American Commercial Operations |
| Veronique Ameye | Executive Vice President & Gen. Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 04, 2024 | 6-K | Filing |
| Mar 21, 2024 | 25-NSE | Filing |
| Feb 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Feb 09, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Feb 06, 2024 | 6-K | Filing |
| Dec 29, 2023 | 6-K | Filing |
| Dec 29, 2023 | SC 13D/A | [Amend] Filing |
| Dec 26, 2023 | SC 13D/A | [Amend] Filing |
| Dec 20, 2023 | SC 13D/A | [Amend] Filing |